Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and x-ray structure analysis

Journal of Medicinal Chemistry

Volumn 42, Issue 11, 1999, Pages 1908-1920

  Matter, Hans ^a   Schwab, Wilfried ^a   Barbier, Denis ^a   Billen, Günter ^a   Haase, Burkhard ^a   Neises, Bernhard ^a   Schudok, Manfred ^a   Thorwart, Werner ^a   Schreuder, Herman ^a   Brachvogel, Volker ^a   Lönze, Petra ^a   Weithmann, Klaus Ulrich ^a  

^a Hoechst Marion Roussel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; TETRAHYDROISOQUINOLINE DERIVATIVE; ZINC;

ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

COLLAGENASES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MATRIX METALLOPROTEINASE 8; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033519654     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980631s     Document Type: Article

References (70)

1. (a) Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
2. (b) Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 1993, 4, 197-250.
3. (c) Murphy, G.; Docherty, A. J. P. The matrix metalloproteinases and their inhibitors. A. J. Res. Cell. Mol. Biol. 1992, 7, 120-125.
4. (d) Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6, 121-125.
5. Lohmander, L. S.; Hoerrner, L. A.; Lark, M. W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthrit. Rheum. 1993, 36, 181-189.
6. Murphy, G.; Hembry, R. M. Proteinases in rheumatoid arthritis. J. Rheumatol. 1992, 19, 61-64.
7. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
8. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schnierer, S.; Tschesche, H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 1994, 13, 1263-1269.
9. (a) Nishino, N.; Powers, J. C. Design of potent reversible inhibitors for thermolysin. Peptides containing zinc coordinating ligands and their use in affinity chromatography. Biochemistry 1979, 18, 4340-4347.
10. (b) Powers, J. C.; Harper, J. W. Inhibitors of metalloproteinases. In Proteinase Inhibitors; Barrett, A. J., Salvesen, G., Eds.; Elsevier: Amsterdam, New York, Oxford, 1986; pp 219-298.
11. (c) Johnson, W. H.; Roberts, N. A.; Borkakoti, N. Collagenase inhibitors: Their design and potential therapeutic use. J. Enzyme Inhib. 1987, 2, 1-22.
12. (d) Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Inhibition of Matrix Metalloproteinases: Structure Based Design. Curr. Pharm. Des. 1996, 2, 624-661.
13. Reinemer, P.; Grams, F.; Huber, R.; Kleine, T.; Schnierer, S.; Pieper, M.; Tschesche, H.; Bode, W. Structural implications for the role of the N-terminus in the 'superactivation' of collagenases. FEBS Lett. 1994, 338, 227-233.
14. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nature Struct. Biol. 1994, 1, 119-123.
15. Grams, F.; Reinemer, P.; Powers, J.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors; implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228, 830-841. The coordinates were obtained prior to submission to PDB due to a collaboration with this group.
16. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure determination and analysis of human collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14020.
17. Kroemer, R. T.; Ettmayer, P.; Hecht, P. 3D-Quantitative Structure - Activity Relationships of Human Immunodeficiency Virus Type-1 Proteinas Inhibitors: Comparative Molecular Field Analysis of 2-Heterosubstituted Statine Derivatives - Implication for the Design of Novel Inhibitors. J. Med. Chem. 1995, 38, 4917-4928.
18. PDB files obtained from Protein Database (National Brookhaven Laboratories): 1MMB, 1MNC, 1KBC, 1JAN, 1JAO, 1JAP, and 1JAQ (http://www.pdb.bnl.gov). Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
19. Cramer, R. D., III; Patterson, D. E.; Bunce, J. E. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
20. Clark, M.; Cramer, R. D., III; Jones, D. M.; Patterson, D. E.; Simeroth, P. E. Comparative Molecular Field Analysis (CoMFA). 2. Towards ist use with 3D-Structural Databases. Tetrahedron Comput. Methods 1990, 3, 47-59.
21. 3D-QSAR in Drug Design. Theory, Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993. This includes many applications and cross-references of the CoMFA methodology in medicinal chemistry.
22. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
23. (a) Wold, S.; Albano, C.; Dunn, W. J.; Edlund, U.; Esbenson, K.; Geladi, P.; Hellberg, S.; Lindberg, W.; Sjöström, M. In Chemometrics: Mathematics and Statistics in Chemistry; Kowalski, B., Ed.; Reidel: Dortrecht, The Netherlands, 1984; pp 17-95.
24. (b) Dunn, W. J.; Wold, S.; Edlund, U.; Hellberg, S.; Gasteiger, J. Multivariate Structure - Activity Relationshiup Between Data from a Battery of Biological Tests and an Ensemble of Structure Descriptors: The PLS Methodol. Quant. Struct.-Act. Relat. 1984, 3, 31-137.
25. (c) Geladi, P. Notes on the History and nature of Partial Least Squares (PLS) Modelling. J. Chemom. 1988, 2, 231-246.
26. (a) Wold, S. Cross-Validatory Estimation of the Number of Component in Factor and Principal Component Models. Technometrics 1978, 4, 397-405.
27. (b) Diaconis, P.; Efron, B. Computer-Intensive Methods for Statistics. Sci. Am. 1984, 116, 96-117.
28. (c) Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, Bootstrapping and Partial Least Squares Compared wih Multile Regression in Conventional QSAR Studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
29. Schlechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
30. Residues and residue numbering rely on the Pro HNC nomenclature: Hasty, K. A.; Pourmotabbed, T. F.; Goldberg, G. I.; Thompson, J. P.; Spinella, D. G.; Stevens, R. M.; Mainardi, C. L. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J. Biol. Chem. 1990, 265, 11421-11424.
31. Hodgson, J. Remodeling MMPIs. Bio/Technology 1995, 13, 554-557.
32. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
33. Burley, S. K.; Petsko, G. A. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 1985, 229, 23-28.
34. Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Matter, H.; Neises, B.; Schudok, M.; Weithmann, K. U. Tetrahydroisoquinoline-3-carboxylate based Matrix Metalloproteinase Inhibitors: Design, Synthesis and Structure - Activity Relationship. Bioorg. Med. Chem. 1999, to be submitted.
35. Thorwart, W.; Schwab, W.; Schudok, M.; Haase, B.; Bartnik, E.; Weithmann, K. U. Preparation of cyclic N-substituted α-iminohydroxamates as matrix metalloproteinase inhibitors. Ger. Offen., 17 pp; Coden: GWXXBX. DE 19542189 A1 970515. CAN 127:50547.
36. Weithmann, K. U.; Schlotte, V.; Jeske, V.; Seiffge, D.; Laber, A.; Haase, B.; Schleyerbach, R. Effects of tiaprofenic acid on urinary pyridinium cross-links in adjuvant arthritic rats: Comparison with doxycycline. Inflamm. Res. 1997, 46, 246-252.
37. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
38. Kabsch, W. Evaluation of single-crystal X-ray diffraction data from a position sensitive detector. J. Appl. Crystallogr. 1988, 21, 916-924.
39. Brünger, A. T. X-PLOR version 3.1, A system for X-ray crystallography and NMR; Yale University Press: New Haven, CT, 1992.
40. SYBYL Molecular Modelling Package, version 6.33; Tripos: St. Louis, MO, 1996.
41. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. J. Comput. Chem. 1989, 10, 982-1912.
42. Gasteiger, J.; Marsili, M. Tetrahedron 1980, 36, 3219-3228. Details of the implementation are given in: Sybyl 6.3 Theory Manual; Tripos: St. Louis, MO, 1996; p 67.
43. Gasteiger, J.; Marsili, M. Tetrahedron 1980, 36, 3219-3228. Details of the implementation are given in: Sybyl 6.3 Theory Manual; Tripos: St. Louis, MO, 1996; p 67.
44. (a) Ghose, A.; Crippen, G. Atomic Physicochemical Parameters for Three-Dimensional Structure-Directed Quantitative Structure - Activity Relationships. 1. Partition Coefficients as a Measure of Hydrophobicity. J. Comput. Chem. 1986, 7, 565-577.
45. (b) Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic Physicochemical Parameters for Three-Dimensional Structure-Directed Quantitative Structure - Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
46. Kearsley, S. K.; Smith, G. M. An Alternative Method for the Alignment of Molecular Structures: Maximizing Electrostatic and Steric Overlap. Tetrahedron Comput. Method 1990, 3, 615-633.
47. (a) Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA Studies and 3D QSAR Publications. In 3D QSAR in Drug Design. Theory, Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, The Netherlands, 1993; pp 711-717.
48. (b) Folkers, G.; Merz, A.; Rognan, D. CoMFA: Scope and Limitations. Ibid.; pp 583-616.
49. (c) Cramer, R. D., III; DePriest, S. A.; Patterson, D. E.; Hecht, P. The Developing Practice of Comparative Molecular Field Analysis. Ibid.; pp 443-485.
50. Sheridan, R. P.; Nachbar, R. B.; Bush, B. L. Extending the trend vector: The trend matrix and sample-based partial least squares. J. Comput.-Aided Mol. Des. 1994, 8, 323-340.
51. For details to compute fingerprints, see UNITY Chemical Information Software, Version 3.0, Reference Guide; Tripos Inc., 1699 S Hanley Rd, St. Louis, MO 63144.
52. (a) Willett, P. Similarity and Clustering in Chemical Information Systems; Research Studies Press: Letchworth, 1987.
53. (b) Willett, P.; Winterman, V. A. Comparison of Some Measures for the Determination of Intermolecular Structural Similarity. Quant. Struct.-Act. Relat. 1986, 5, 18-25.
54. Lajiness, M.; Johnson, M. A.; Maggiora, G. M. Implementing Drug Screening Programs using Molecular Similarity Methods. In QSAR: Quantitative Structure - Activity Relationships in Drug Design; Fauchere, J. L., Ed.; Alan R. Liss Inc.: New York, 1989; pp 173-176.
55. Taylor, R. Simulation Analysis of Experimental Design Strategies for Screening Random Compounds as Potential New Drugs and Agrochemicals. J. Chem. Inf. Comput. Sci. 1995, 35, 59-67.
56. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
57. 50 × 100000).
58. Clark, M.; Cramer, R. D., III. The Probability of Chance Correlation using Partial Least Squares (PLS). Quant. Struct.-Act. Relat. 1993, 12, 137-145.
59. G. Cruciani, S. Clementi, personal communication.
60. Carpignano, R.; Dolci, M.; Scarfi, D. Design of more informative molecules for QSAR study in a series of juvenile hormones. In Trends QSAR Mol. Modelling 92, Proc. Eur. Symp. Struct.-Act. Relat.; Wermuth, C.-G., Ed.; ESCOM: Leiden, The Netherlands, 1993.
61. (a) Norinder, U.; Hoegberg, T. PLS-based quantitative structure -activity relationship for substituted benazmides of clebopride type. Application of experimental design in drug research. Acta Chem. Scand. 1992, 46, 363-366.
62. (b) Norinder, U. Experimental design-based quantitative structure-toxicity relationship of some local anestetics using the PLS method. J. Appl. Toxicol. 1992, 12, 143-147.
63. (c) Norinder, U. An experimental design based quantitative structure - activity relationship study on β-adrenergic blocking agents using PLS. Drug Des. Discov. 1991, 8, 127-136.
64. (d) Norinder, U. Experimental design based 3D QSAR analysis of steroid-protein interaction: application to human CBG complexes. J. Comput.-Aided Mol. Des. 1990, 4, 381-389.
65. Pötter, T.; Matter, H. Random or Rational Design ? Evaluation of Diverse Compound Subsets from Chemical Structure Databases. J. Med. Chem. 1998, 41, 478-488.
66. Betz, M.; Huxley, P.; Davies, S. J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Rüth, F. X. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247, 356-363.
67. Chapman, K. T.; Durette, P. L.; Caldwell, C. G.; Sperow, K. M.; Niedzwiecki, L. M.; Harrison, R. K.; Saphos, C.; Christen, A. J.; Olszewski, J. M.; Moore, V. L.; Maccoss, M.; Hagmann, W. K. Orally Active Inhibitors of Stromelysin-1 (MMP-3). Bioorg. Med. Chem. Lett. 1996, 6, 803-806.
68. (a) Caldwell, C. G.; Sahoo, S. P.; Polo, S. A.; Eversole, R. R.; Lanza, T. J.; Mills, S. G.; Niedzwiecki, L. M.; Izquierdo-Martin, M.; Chang, B. C.; Harrison, R. K.; Kuo, D. W.; Lin, T. Y.; Stein, R. L.; Durette, P. L.; Hagmann, W. K. Phosphinic Acid Inhibitors of Matrix Metalloproteinases. Bioorg. Med. Chem. Lett. 1996, 6, 323-328.
69. (b) Chapman, K. T.; Wales, J.; Sahoo, S. P.; Niedzwiecki, L. M.; Izquierdo-Martin, M.; Chang, B. C.; Harrison, R. K.; Stein, R. L.; Hagmann, W. K. Inhibition of Matrix Metalloproteinases by P1 Substituted N-Carboxyalkyl Dipeptides. Bioorg. Med. Chem. Lett. 1996, 6, 329-332.
70. (c) Beeley, N. R. A.; Ansell, P. R. J.; Docherty, A. J. P. Curr. Opin. Ther. Pat. 1994, 4, 7-17.